Ferramentas Pessoais
Você está aqui: Entrada Notícias Bruno Sarmento

Bruno Sarmento

HCP_EIS2018_BSarmento.jpg

 

 

 
Bruno Sarmento
Researcher, INEB/i3S

ABOUT THE SPEAKER:

Bruno Sarmento is the Group Leader of the Nanomedicines and Translational Drug Delivery group at Institute of Biomedical Engineering/Institute for Investigation and Innovation in Health (INEB/i3S), University of Porto, Portugal and Assistant Professor at IUCS/CESPU. His current research is focused on the development of functionalized nanomedicines and their application in the pharmaceutical and biomedical fields. In particular, he is interested in the establishment of nanoformulations of advanced functional biomaterials and understand their interaction with cells and biological surfaces, with interest in diabetes, cancer and infectious diseases. He published more than 250 papers in international peer reviewed (ISI) journals (H index 39), 37 book chapters and more than 250 presentations in International Congresses. He edited 5 books in the field of nanomedicine, biomaterials and biological barriers. He is member of the Editorial Advisory Board of several international journals and has acted as referee for top-ranked journals and funding agencies.

 

ABOUT THE PRESENTATION:

"Nanomedicines can improve the efficacy of old drugs molecules into outstanding products"

Successful drug therapy requiring frequent doses heavily relies on patient compliance. The easiest and most economical way is through self-administered, mucosal delivery. However, due to enzymatic degradation, and/or impermeability of the mucosal or epithelial barriers, many drugs are administrated through painful injections that reduce this compliance gap and require specialized health caretakers. Nanotechnology is presented as the most promising strategy to improve drug physicochemical (solubility), biophysical (conformational and structural stability), and biopharmaceutical (permeability, metabolic stability) properties, providing stability for encapsulated molecules in the harsh environment of the physiologic fluidics, surpassing mucus barrier and guiding payloads to the local of absorption, ultimately increasing bioavailability.

 

[voltar ao programa | back to the programme]